Date: 2017-08-09
Type of
information: Initiation of the trial
phase:
Announcement: initiation of the trial
Company: PharmaMar (Spain)
Product: Aplidin® (plitidepsin) in combination with pomalidomide, bortezomib and dexamethasone
Action
mechanism: depsipeptide derivative. Plitidepsin is an investigational anticancer agent of marine origin, originally obtained from the tunicate Aplidium albicans. It specifically binds to the eEF1A2 and targets the non-canonical role of this protein, resulting in tumor cell death via apoptosis.
Disease: multiple myeloma
Therapeutic
area: Cancer - Oncology
Country: Czech Republic, Spain
Trial
details:
Latest
news:
- • On August 9, 2017, PharmaMar announced the start of a multicenter quadruple combination clinical study with Aplidin® (plitidepsin), along with pomalidomide, bortezomib and dexamethasone, products, for the treatment of multiple myeloma. The main objective of this study is to evaluate the recommended dose (RD), the efficacy of the combination along with the safety profile, evaluating potential response and resistance markers, amongst other parameters. The study will follow the same line in combating multiple myeloma with compounds that have different mechanisms of action to increase the success rate. Aplidin® has already demonstrated, through other studies, its potential in combining with other compounds, due to its lack of hematological toxicity. Given this, Aplidin® can be administered at a maximum dose, with the corresponding increase in efficacy of the therapy. This will put Aplidin® on the first line of multiple myeloma treatment. Various centers, both in Spain and in the Czech Republic are taking part.
Is
general: Yes
